


Repirinast

Cat. No.:	HY-109544
CAS No.:	73080-51-0
Molecular Formula:	C ₂₀ H ₂₁ NO ₅
Molecular Weight:	355.38
Target:	Histamine Receptor
Pathway:	GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Repirinast (MY-5116) is an orally active anti-allergic agent. Repirinast inhibits histamine release. Repirinast can be used in the research of bronchial asthma ^{[1][2][3]} .																
In Vitro	Repirinast inhibits histamine release from rat peritoneal mast cells induced by antigen (IC ₅₀ : 0.3 μM) ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.																
In Vivo	<p>Repirinast (30 mg/kg, i.p.) inhibits antigen-induced early and late pulmonary responses in guinea pigs^[1]. Repirinast (30 mg/kg, p.o.) inhibits antigen-induced immediate bronchoconstriction in rats^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Guinea pigs^[1]</td> </tr> <tr> <td>Dosage:</td> <td>30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection (i.p.)</td> </tr> <tr> <td>Result:</td> <td>Inhibited leukocyte (predominantly eosinophils) infiltration into bronchial tissue. Blocked antigen-induced airway hyperresponsiveness to inhaled Acetylcholine.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Rat with asthma (challenged with 10 mg/kg antigen OVA)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral administration (p.o.)</td> </tr> <tr> <td>Result:</td> <td>Inhibited the decreases in the number Of breath at 30 sec and 1 min after challenge.</td> </tr> </table>	Animal Model:	Guinea pigs ^[1]	Dosage:	30 mg/kg	Administration:	Intraperitoneal injection (i.p.)	Result:	Inhibited leukocyte (predominantly eosinophils) infiltration into bronchial tissue. Blocked antigen-induced airway hyperresponsiveness to inhaled Acetylcholine.	Animal Model:	Rat with asthma (challenged with 10 mg/kg antigen OVA) ^[1]	Dosage:	30 mg/kg	Administration:	Oral administration (p.o.)	Result:	Inhibited the decreases in the number Of breath at 30 sec and 1 min after challenge.
Animal Model:	Guinea pigs ^[1]																
Dosage:	30 mg/kg																
Administration:	Intraperitoneal injection (i.p.)																
Result:	Inhibited leukocyte (predominantly eosinophils) infiltration into bronchial tissue. Blocked antigen-induced airway hyperresponsiveness to inhaled Acetylcholine.																
Animal Model:	Rat with asthma (challenged with 10 mg/kg antigen OVA) ^[1]																
Dosage:	30 mg/kg																
Administration:	Oral administration (p.o.)																
Result:	Inhibited the decreases in the number Of breath at 30 sec and 1 min after challenge.																

REFERENCES

[1]. N Yamada, et al. Repirinast inhibits antigen-induced early and late pulmonary responses and airway hyperresponsiveness in guinea pigs. *Int Arch Allergy Immunol.* 1993;100(4):367-72.

[2]. Takahashi K. Effects of MY-5116 on experimental asthma in rats and guinea pigs. *Arerugi*. 1986 Oct; 35(10): 1037-46.

[3]. M Takei, et al. Inhibition of histamine release from rat peritoneal mast cells by MY-1250, an active metabolite of Repirinast (MY-5116). *Int Arch Allergy Appl Immunol*. 1990;93(2-3):237-41.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA